AbbVie

ABBVPre-clinical

North Chicago, United Statesabbviecontractmfg.com

AbbVie Inc. is a research-based biopharmaceutical company formed in 2013 as a spinoff from Abbott Laboratories. The company focuses on developing and delivering innovative therapies that address some of the world's most complex and serious diseases. With a strong portfolio led by immunology treatments and a growing oncology franchise, AbbVie has established itself as a leader in specialty therapeutics with global operations and a commitment to advancing patient care.

Market Cap

$74.8B

Founded

2013

Employees

45,000-50,000

Focus

AntibodiesBiologicsSmall Molecules

ABBV · Stock Price

USD 62.22+27.10 (+77.16%)

Historical price data

AI Company Overview

Technology Platform

Multi-modal drug discovery and development platform encompassing small molecules, biologics, and advanced drug delivery systems with particular expertise in immunology, oncology, and neuroscience therapeutics.

Pipeline Snapshot

1000

1000 drugs in pipeline, 323 in Phase 3

Drug	Indication	Stage
Epcoritamab + Rituximab + Lenalidomide + Oxaliplatin + Gemcitabine	Diffuse Large B-Cell Lymphoma	Phase 3
BOTOX + Placebo	Episodic Migraine	Phase 3
Adalimumab + Placebo	Ulcerative Colitis	Phase 3
Levodopa-Carbidopa Intestinal Gel (LCIG)	Advanced Parkinson's Disease	Phase 3
ombitasvir/paritaprevir/ritonavir and dasabuvir + Ribavirin	Chronic Hepatitis C	Phase 3

Funding History

IPOUndisclosedUndisclosedJan 2, 2013

FDA Approved Drugs

EMRELISBLAMay 14, 2025

EMBLAVEONDAFeb 7, 2025

VYALEVNDAOct 16, 2024

Opportunities

AbbVie has significant growth opportunities through its next-generation immunology portfolio expansion, oncology pipeline development, and geographic expansion in emerging markets.

The company's strong cash generation provides flexibility for strategic acquisitions and continued R&D investment.

Risk Factors

Key risks include the ongoing Humira patent cliff and biosimilar competition, regulatory uncertainties in drug development, and increasing pricing pressure from payers globally.

The company must successfully execute on its post-Humira strategy to maintain growth momentum.

Competitive Landscape

AbbVie competes with major pharmaceutical companies like J&J, Roche, and Pfizer across multiple therapeutic areas. The company differentiates through its deep immunology expertise, strong commercial execution, and robust pipeline, though faces intense competition from both established players and emerging biotech companies.

Publications

Patents

Pipeline

1000

FDA Approvals